Income Statement

4D MOLECULAR THERAPEUTICS, INC.

FDMT
Annual
Performance Overview Click any row in the table to add it to this chart
in millions USD
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY
Revenue
85.21 0.04 20.72 3.13 18.04 13.61
Cost of Revenue
- - - - - -
Gross Profit
85.21 0.04 20.72 3.13 18.04 13.61
Operating Expenses
244.76 187.88 133.59 113.16 89.37 70.28
Research & Development
195.70 141.30 97.10 80.25 61.36 53.04
Selling, General & Administrative
49.06 46.58 36.49 32.91 28.01 17.24
Other Operating Expenses
- - - - - -
Operating Income
-159.55 -187.84 -112.87 -110.03 -71.33 -56.66
Non-Operating Income
19.44 26.97 12.03 2.54 0.02 -0.03
Interest Income
19.48 27.05 12.21 2.57 0.14 0.15
Interest Expense
- - - - - -
Other Non-Op Income / Expense
-0.04 -0.08 -0.18 -0.04 -0.12 -0.18
Income Before Tax
- - - - - -
Income Tax Expense
- - - - - -
Non-Controlling Interest
- - - - - -
Net Income
-140.11 -160.87 -100.84 -107.49 -71.32 -56.69
Supplemental Per share data, derived & other items — not part of the income statement
in millions USD unless noted
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY
Depreciation & Amortization
- - - - - -
EBITDA
-154.85 -183.19 -108.66 -107.63 -69.81 -55.22
Earnings Per Share (Basic)
-2.42 -2.98 -2.58 -3.32 - -
Diluted EPS
-2.42 -2.98 -2.58 -3.32 - -
Weighted Average Shares
57.93 53.94 39.13 32.35 - -
Diluted Weighted Avg Shares
57.93 53.94 39.13 32.35 - -
Comprehensive Income
-139.61 -160.66 -99.63 -108.27 -71.74 -